Literature DB >> 16721272

The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion.

Balázs Hauser1, Michael Gröger, Ulrich Ehrmann, Maura Albicini, Uwe Bernd Brückner, Hubert Schelzig, Balasubramanian Venkatesh, Hongshan Li, Csaba Szabó, Günter Speit, Peter Radermacher, Jochen Kick.   

Abstract

Inhibition of poly (ADP-ribose) polymerase 1 (PARP-1) improved hemodynamics and organ function in various shock models induced by sepsis or ischemia/reperfusion. PARP-1, however, is also referred to play a pivotal role for the maintenance of genomic integrity. Therefore, we investigated the effect of the PARP-1 blocker INO-1001 on hemodynamics, kidney function, and DNA damage and repair during porcine thoracic aortic cross-clamping. The animals underwent 45 min of aortic cross-clamping after receiving vehicle (n=9) or i.v. INO-1001 (n=9; total dose, 4 mg.kg, administered both before clamping and during reperfusion), data were recorded before clamping, before declamping, and 2 and 4 h after declamping. During reperfusion, continuous i.v. norepinephrine was incrementally adjusted to maintain blood pressure greater than or equal to 80% of the pre-clamping level. The plasma INO-1001 levels analyzed with high-pressure liquid chromatography were 1 to 1.4 micromol/L and 0.4 to 0.6 micromol/L before and after clamping, respectively. Although INO-1001-treated animals required less norepinephrine support, kidney function was comparable in the 2 groups. There was no intergroup difference either in the time course of DNA damage and repair (comet assay) as assessed both in vivo in whole blood before surgery, before clamping, before declamping, 2 h after declamping, and ex vivo in isolated lymphocytes (Ficoll gradient) sampled immediately before clamping and analyzed before, immediately, and 1 and 2 h after exposure to 4 bar 100% O2 for 2 h. There was no difference either in the expression of the cyclin-dependent kinase inhibitor gene, p27, in the kidney (immunohistochemistry). The reduced norepinephrine requirements during reperfusion suggest a positive inotropic effect of INO-1001, as demonstrated by other authors. In our model, INO-1001 proved to be safe with respect to DNA repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721272     DOI: 10.1097/01.shk.0000209561.61951.2e

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  15 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

2.  Novel modulators of poly(ADP-ribose) polymerase.

Authors:  Csaba Szabo; Pal Pacher; Raymond A Swanson
Journal:  Trends Pharmacol Sci       Date:  2006-10-19       Impact factor: 14.819

3.  The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.

Authors:  Akbar Ahmad; Juliana de Camargo Vieira; Aline Haas de Mello; Thais Martins de Lima; Suely Kubo Ariga; Denise Frediani Barbeiro; Hermes Vieira Barbeiro; Bartosz Szczesny; Gábor Törö; Nadiya Druzhyna; Elisa B Randi; Michela Marcatti; Tracy Toliver-Kinsky; András Kiss; Lucas Liaudet; Reinaldo Salomao; Francisco Garcia Soriano; Csaba Szabo
Journal:  Pharmacol Res       Date:  2019-05-06       Impact factor: 7.658

4.  Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.

Authors:  Soo-Kyoung Choi; Maria Galán; Modar Kassan; Megan Partyka; Mohamed Trebak; Khalid Matrougui
Journal:  Hypertension       Date:  2012-03-26       Impact factor: 10.190

5.  The world according to poly(ADP-ribose) polymerase (PARP)--update 2006.

Authors:  Eberhard Barth; Peter Radermacher; Csaba Szabó
Journal:  Intensive Care Med       Date:  2006-08-23       Impact factor: 17.440

Review 6.  Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health.

Authors:  Carlos W Nossa; Steven R Blanke
Journal:  Gut Microbes       Date:  2010 Nov-Dec

7.  Right man, right time, right place?--on the time course of the mediator orchestra in septic shock.

Authors:  Balázs Hauser; Peter Radermacher
Journal:  Crit Care       Date:  2010-08-23       Impact factor: 9.097

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 9.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

10.  The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury.

Authors:  Christian Maier; Angelika Scheuerle; Balázs Hauser; Hubert Schelzig; Csaba Szabó; Peter Radermacher; Jochen Kick
Journal:  Intensive Care Med       Date:  2007-03-15       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.